Brisbane, Australia – 23rd April 2019

Ellume Limited (Ellume) is pleased to announce the appointment of David Green as Chief Financial Officer and Company Secretary, and Mark Boyle Chief Business Officer of the Company. These appointments strengthen the management of the company in preparation for US commercialisation and potential ASX IPO later this year.

David Green has over 25 years’ experience in senior finance roles covering private treaty and public company transactions, with a strong background in pre-IPO and start-up businesses. David commenced his career with EY in both England and Australia, and has since gone on to CFO roles with a number of ASX listed entities including Sigma Pharmaceuticals and Alchemia Limited. He has also worked alongside CEOs in capital raising activities including seed funding and IPOs.

Mark Boyle brings over 20 years’ of executive management experience in in-vitro diagnostic and biotechnology markets to his new role in the US. Previously, he was the President of Cellestis Inc. and continued on through the acquisition by Qiagen to successfully lead the company’s global business portfolio in tuberculosis management. During his tenure from 2001 to 2016, sales of QuantiFERON diagnostics grew to more than US $100M in recurring revenue. More recently, Mark was President IVD, with Clinical Genomics. Mark is based in Valencia, California.

“Mark and David both bring formidable experience and leadership to our expanding team,” said Founder and Managing Director Dr Sean Parsons. “Mark’s experience in successfully scaling the sales of QuantiFERON in the US gives us confidence and a successful framework as we prepare to replicate this with our ellume·lab product, and David’s experience with public markets at Sigma, Alchemia and others is proving fundamental as we position the company to potentially transition onto the ASX later this year.”

In January 2019, Ellume received $US 15 million from German biotech Qiagen as part of its strategic partnership to build on the successful QuantiFERON TB diagnostic business. Ellume also announced a global partnership with GlaxoSmithKline in December 2018 on consumer products.

ENDS